Abstract: The present invention relates to a series of compounds for regulating activity of a protein kinase, in particular a compound for inhibiting activity of PLK1. The present invention further provides a pharmaceutical composition containing the compound, and a use of the compound and the pharmaceutical composition thereof in preparing a drug for preventing or treating diseases caused by and/or related to dysregulation of PLK1 kinase activity.

Abstract: The present disclosure provides LPA antagonists, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating LPA-associated diseases, disorders, and conditions.

Abstract: The present disclosure provides compounds for modulating calcitonin receptor and/or amylin receptor activity, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating a calcitonin receptor and/or amylin receptor associated disease or disorder.

Abstract: An embodiment of the present application discloses a backlight module and a display device disposing a support member between a flexible circuit board and a backplate. Also, an elastic modulus of the support member is greater than an elastic modulus of the flexible circuit board.

Abstract: This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

Abstract: The present disclosure provides compounds for modulating calcitonin receptor and/or amylin receptor activity, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating a calcitonin receptor and/or amylin receptor associated disease or disorder.

Abstract: This disclosure relates to GLP-1 agonists of Formula I. including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

Abstract: This disclosure relates to GLP-1 agonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

Abstract: The present invention relates to a compound of formula (X) or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof, and a pharmaceutical composition containing the compound and a use.

Abstract: The present disclosure provides compounds for modulating calcitonin receptor and/or amylin receptor activity, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating a calcitonin receptor and/or amylin receptor associated disease or disorder.

Abstract: This disclosure relates to GLP-1 agonists of Formula I: including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

Abstract: A backlight module and a display device are disclosed. The light-guiding structure includes a first light-guiding surface opposite to the first light-emitting member and a second light-guiding surface opposite to the second light-emitting member, the first light-guiding surface has a specular reflective surface, and the second light-guiding surface has a diffuse reflective surface. When the backlight module is configured in the first state, the first light-emitting member emits lights, the second light-emitting member does not emit lights. When the backlight module is configured in the second state, at least the second light-emitting member emits lights.

Abstract: Provided are a heterocyclic compound used as a TAAR1 agonist, a preparation method of the compound, a pharmaceutical composition containing the compound, and a use of the compound as a TAAR1 agonist in preventing and/or treating various CNS-related diseases. Each substituent in the general formula (IA) is the same as defined in the description.

Abstract: The present disclosure provides compounds for modulating calcitonin receptor and/or amylin receptor activity, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating a calcitonin receptor and/or amylin receptor associated disease or disorder.

Abstract: The present disclosure provides LPA antagonists, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating LPA-associated diseases, disorders, and conditions.

Abstract: In some implementations, a storage node receives data processing instructions from a compute node of a network architecture. The storage node detects a Directed Acyclic Graph (DAG) within the data processing instructions. The DAG includes a plurality of data processing operations arranged within the DAG according to an execution. The data processing operations further include user-defined function (UDF) information associated with a UDF. The storage node may retrieve a first data object from an object store of the distributed storage node based on object keys information within the plurality of data processing operations. The storage node may execute the plurality of data processing operations using the retrieved first data object to generate a DAG execution result, the executing of the plurality of data processing operations based on the execution order. The storage node may communicate the DAG execution result to the compute node in response to the data processing instructions.

Abstract: A backlight module and a display device are disclosed. The light-guiding structure includes a first light-guiding surface opposite to the first light-emitting member and a second light-guiding surface opposite to the second light-emitting member, the first light-guiding surface has a specular reflective surface, and the second light-guiding surface has a diffuse reflective surface. When the backlight module is configured in the first state, the first light-emitting member emits lights, the second light-emitting member does not emit lights. When the backlight module is configured in the second state, at least the second light-emitting member emits lights.

Abstract: The present disclosure provides compounds for modulating calcitonin receptor and/or amylin receptor activity, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating a calcitonin receptor and/or amylin receptor associated disease or disorder.

Abstract: This disclosure relates to GLP-1 agonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

Abstract: The present disclosure relates generally to GLP-1 agonists and pharmaceutical compositions comprising the same, as well as methods for treating a GLP-1 associated disease, disorder, or condition.